Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on Thursday, February 6, 2025, at 10:00 a.m. Eastern time.
The presentation will be accessible through a live audio webcast at the provided link, and an archived version will remain available on the Keros website's Investor section for up to 90 days after the event. This presentation represents an opportunity for investors and interested parties to gain insights into the company's developments and strategies.
Keros Therapeutics (NASDAQ: KROS), un'azienda biofarmaceutica in fase clinica specializzata nei disturbi della segnalazione delle proteine della famiglia TGF-ß, ha annunciato la sua prossima partecipazione alla Guggenheim SMID Cap Biotech Conference. Il Presidente e CEO dell'azienda, Jasbir S. Seehra, Ph.D., parteciperà a una presentazione in stile fireside chat giovedì 6 febbraio 2025, alle 10:00 ora orientale.
La presentazione sarà disponibile attraverso un webcast audio dal vivo al link fornito, e una versione archiviata resterà disponibile nella sezione Investitori del sito web di Keros per un massimo di 90 giorni dopo l'evento. Questa presentazione rappresenta un'opportunità per investitori e parti interessate di ottenere approfondimenti sui sviluppi e le strategie dell'azienda.
Keros Therapeutics (NASDAQ: KROS), una compañía biofarmacéutica en etapa clínica especializada en trastornos de señalización de proteínas de la familia TGF-ß, ha anunciado su próxima participación en la Guggenheim SMID Cap Biotech Conference. El Presidente y CEO de la compañía, Jasbir S. Seehra, Ph.D., participará en una presentación estilo fireside chat el jueves 6 de febrero de 2025, a las 10:00 a.m. hora del Este.
La presentación será accesible a través de un webcast de audio en vivo en el enlace proporcionado, y una versión archivada estará disponible en la sección de Inversores del sitio web de Keros durante hasta 90 días después del evento. Esta presentación representa una oportunidad para que inversores y partes interesadas obtengan información sobre los desarrollos y estrategias de la empresa.
Keros Therapeutics (NASDAQ: KROS), TGF-ß 가족 단백질 신호 장애를 전문으로 하는 임상 단계의 생물 제약 회사가 구겐하임 SMID 캡 생명공학 회의에 참여할 예정이라고 발표했습니다. 회사의 의장 겸 CEO인 Jasbir S. Seehra 박사는 2025년 2월 6일 목요일 오전 10시 동부 표준시에 진행될 fireside 채팅 프레젠테이션에 참여할 것입니다.
프레젠테이션은 제공된 링크를 통해 라이브 오디오 웹캐스트로 접근할 수 있으며, 행사 후 최대 90일 동안 Keros 웹사이트의 투자자 섹션에서 아카이브 버전을 찾을 수 있습니다. 이 프레젠테이션은 투자자 및 이해관계자에게 회사의 발전 및 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Keros Therapeutics (NASDAQ: KROS), une entreprise biopharmaceutique en phase clinique spécialisée dans les troubles de la signalisation des protéines de la famille TGF-ß, a annoncé sa prochaine participation à la Guggenheim SMID Cap Biotech Conference. Le Président et CEO de l'entreprise, Jasbir S. Seehra, Ph.D., participera à une présentation de type fireside chat le jeudi 6 février 2025, à 10h00, heure de l'Est.
La présentation sera accessible via un webcast audio en direct au lien fourni, et une version archivée sera disponible dans la section Investisseurs du site web de Keros pendant jusqu'à 90 jours après l'événement. Cette présentation représente une opportunité pour les investisseurs et les parties intéressées d'obtenir des éclaircissements sur les développements et les stratégies de l'entreprise.
Keros Therapeutics (NASDAQ: KROS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Störungen der TGF-ß-Protein-Signalgebung spezialisiert hat, hat seine bevorstehende Teilnahme an der Guggenheim SMID Cap Biotech Conference angekündigt. Der Vorsitzende und CEO des Unternehmens, Jasbir S. Seehra, Ph.D., wird am Donnerstag, den 6. Februar 2025, um 10:00 Uhr Eastern Time an einer Fireside-Chat-Präsentation teilnehmen.
Die Präsentation wird über einen Live-Audio-Webcast unter dem bereitgestellten Link zugänglich sein, und eine archivierte Version wird bis zu 90 Tage nach der Veranstaltung im Investorenbereich der Keros-Website verfügbar bleiben. Diese Präsentation stellt eine Gelegenheit für Investoren und Interessierte dar, Einblicke in die Entwicklungen und Strategien des Unternehmens zu erhalten.
- None.
- None.
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time.
A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/guggen2/kros/2033361 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros’ product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros’ most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
When is Keros Therapeutics (KROS) presenting at the Guggenheim SMID Cap Biotech Conference?
How can investors access the KROS presentation at the Guggenheim Conference?
How long will the KROS Guggenheim Conference presentation replay be available?
What type of presentation will KROS deliver at the Guggenheim SMID Cap Conference?
What is the therapeutic focus of Keros Therapeutics (KROS)?
